Analysis of simulated clinical trials

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective

Volumn , Issue , 2002, Pages 131-152

  Ette, Ene I ^a   Godfrey, Christopher J ^a   Ogenstad, Stephan ^a   Williams, Paul J ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12844282659     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. CC Peck. Drug development: improving the process. Food and Drug Law J 52(2): 163-167, 1997.
2. M Hale, WR Gillespie, SK Gupta, B Tuk, NH Holford. Clinical trial simulation: streamlining your drug development process. Appl Clinic Trials 5:35-40, 1996.
3. US Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. February 1999. http://www.fda.gov/cder/guidance/index.htm
4. H Sun, EO Fadiran, CD Jones, L Lesko, SM Huang, K Higgins, C Hu, S Machado, S Maldonado, R Williams, M Hossain, EI Ette. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 37:41-58, 1999.
5. NHG Holford, HC Kimko, JPR Monteleone, CC Peck. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40:209-234, 2000.
6. DR Jones. Computer simulation as a tool for clinical trial design. Int J Bio-Med Comp 10:145-150, 1979.
7. KL Lee, M Frederick, CF Starmer, PJ Harris, RA Rosati. Clinical judgment and statistics: lessons from a simulated randomized trial in coronary artery disease. Circulation 61(3):508-515, 1980.
8. MD Hale, AJ Nicholls, RE Bullingham, R Hene, A Hoitsma, JP Squifflet, W Weimar, Y Vanrenterghem, FJ Van de Woude, GA Verpooten. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64:672-683, 1998.
9. Y Hashimoto, LB Sheiner. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 19:333-353, 1991.
10. MK Al-Banna, AW Kelman, B Whiting. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 18:347-360, 1990.
11. EI Ette, AW Kelman, CA Howie, B Whiting. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters. Ann Pharmaco-ther 27:1034-1039 and Correction 27:1548, 1993.
12. EI Ette, AW Kelman, CA Howie, B Whiting. Inter-animal variability and parameter estimation in preclinical animal pharmacokinetic studies. Clin Research Regul Affairs 11(2):121-139, 1994.
13. EI Ette, H Sun, TM Ludden. Design of population pharmacokinetic studies. Proc Am Stat Assoc (Biopharmaceutics Section), 487-489, 1994.
14. CD Jones, H Sun, EI Ette. Designing cross-sectional pharmacokinetic studies: implications for pediatric and animal studies. Clin Res Regul Affairs 13(3,4):133-165, 1996.
15. NE Johnson, JR Wade, MO Karlsson. Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 24(6):245-272, 1996.
16. H Sun, EI Ette, TM Ludden. On error in the recording of sampling times and parameter estimation from repeated measures pharmacokinetic data. J Pharmacokinet Biopharm 24(6):635-648, 1996.
17. C Veyrat-Follet, R Bruno, R Olivares, GR Rhodes, P Chaikin. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 68(6):677-687, 2000.
18. P Williams, JR Lane, CC Turkel, EV Capparelli, Z Dziewanowska, AW Fox. Di-chloroacetate: population pharmacokinetics with a pharmacodynamic sequential link model. J Clin Pharmacol 41:259-267, 2001.
19. GV Glass. Primary, secondary and meta-analysis of research. Educ Res 5:3-8, 1976.
20. K Dickersin, JA Berlin. Meta-analysis: state-of-science. Epidemiol Rev, 14:154-176, 1992.
21. EI Ette. Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial. Ann Pharmacother 32:818-828, 1998.
22. KG Kowalski, MM Hutmacher. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 20:75-91, 2001.
23. SL Beal, LB Sheiner. NONMEM Users Guide, parts I-VI. San Francisco, CA: Division on Clinical Pharmacology, University of San Francisco, 1979-1992.
24. NHG Holford, M Hale, HC Ko, J-L Steimer, LB Sheiner, CC Peck. Simulation in Drug Development: Good Practices. Washington, DC: CDDS, Georgetown University, 1999. http://cdds.georgetown.edu
25. Pinheiro JC, Bates DM, eds. Mixed-Effects Models in S and S-PLUS. New York: Springer, 2000.
26. DO Stram, JW Lee. Variance components testing in the longitudinal mixed effects model. Biometrics 50:1171-1177, 1994.
27. U Wahlby, EN Jonsson, MO Karlsson. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252, 2001.
28. Gelman A, Carlin JB, Stern HS, Rubin DB, eds. Bayesian Data Analysis. London: Chapman and Hall, 1995.
29. P Bauer. Multiple testing in clinical trials. Stat Med 10:871-890, 1991.
30. G Hommel. Tests of overall hypothesis for arbitrary dependent structures. Biometrical J 25(5):423-430, 1983.
31. G Hommel. Multiple test procedures for arbitrary dependence structures. Metrika 33(6):321-336, 1986.
32. W Lehmacher, G Wassmer, P Reimer. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrika 67:655-660, 1991.
33. PC O’Brien. Procedures for comparing samples with multiple endpoints. Biometrics 40:1079-1089, 1984.
34. SJ Pocock, NL Geller, A Tsiatis. The analysis of multiple endpoints in clinical trials. Biometrics 43:487-498, 1987.
35. AJ Sankoh, MF Huque. A note on O’Briens OLS and GLS tests. Biometrics 51: 1580-1581, 1995.
36. DI Tang, C Gnecco, NL Geller. Design of group sequential trials with multiple endpoints. J Am Stat Assoc 84:776-779, 1989.
37. DI Tang, C Gnecco, NL Geller. An approximate likelihood ratio test for a normal mean vector with nonnegative components with application to clinical trials. Biome-trika 76:751-754, 1989.
38. DI Tang, NL Geller, SJ Pocock. On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics 49:23-30, 1993.
39. S Holm. A simple sequentially rejective Bonferroni Test Procedure. Scandinavian Journal of Statistics 6:65-70, 1979.
40. RJ Simes. An improved Bonferroni procedure for multiple tests of significance. Bio-metrika 67:655-660, 1976.
41. Y Hochberg. A sharper Bonferroni procedure for multiple significance testing. Bio-metrika 75:800-803, 1988.
42. G Hommel. A comparison of two modified Bonferroni procedures. Biometrika 76: 624-625, 1989.
43. GA Hommel. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75:383-386, 1988.
44. CW Dunnet, AC Tamhanne. A step-up multiple test procedure. J Am Stat Assoc 87:162-170, 1993.
45. JW Tukey, JL Ciminera, JF Heyse. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41:295-301, 1985.
46. SD Dubey. Adjustment of p values for multiplicities of intercorrelating symptoms. Proceedings of the VIth International Society of Clinical Biostatisticians, Germany, 1985.
47. P Armitage, M Parmar. Some approaches to the problem of multiplicity in clinical trials. Proceedings of the XlIth International Biometrics Conference, Seattle, Washington, 1986.
48. EI Ette, P Williams, H Sun, FO Ajayi, LC Onyiah. The process of knowledge discovery from large pharmacokinetic data sets. J Clin Pharmacol 41:25-54, 2001.
49. WS Cleveland, R McGill. Graphical perception and graphical methods of analyzing scientific data. Science 229:828-833, 1985.
50. GE Legge, Y Gu, A Luebker. Efficiency of graphical perception. Percep Psychophys 46:365-374, 1989.
51. JS Hollands, I Spence. Judgement of change and proportion in graphical perception. Human Factors 34:313-334, 1992.
52. EI Ette, H Sun, TM Ludden. Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol 38:417-423, 1998.
53. EO Fadiran, CD Jones, EI Ette. Designing population pharmacokinetic studies: performance of mixed designs. Eur J Drug Metab Pharmacokinet 25:231-239, 2000.
54. WS Cleveland. Visualizing Data. Summit, NJ: Hobart Press, 1993.
55. MD Hale. Using population pharmacokinetics for planning a randomized concentration-controlled trial with a binary response. In: L Aarons, LP Balant, M Danhof, M Gex-Fabry, UA Gundert-Remy, MO Karlsson, F Mentre, PL Morselli, F Rom-bout, M Rowland, JL Steimer, S Vozeh, eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; Brussels 1997, pp 228-235.